Aarti Drugs Reports Strong Profit Growth Amid Liquidity Concerns in July 2025 Results
Aarti Drugs has reported its financial results for the quarter ending June 2025, showing a Profit After Tax of Rs 53.91 crore, a 28.2% increase from the previous average. However, the company faces liquidity challenges, with cash and cash equivalents at their lowest in recent periods.
Aarti Drugs, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending June 2025. The results, declared on July 18, 2025, indicate a notable shift in the company's evaluation, with its score adjusting from 7 to 3 over the past three months.The financial data reveals that Aarti Drugs achieved a Profit After Tax (PAT) of Rs 53.91 crore for the quarter, reflecting a growth of 28.2% compared to the average PAT of Rs 42.04 crore from the previous four quarters. This positive trend in PAT suggests a strengthening in the company's profitability on a quarterly basis.
However, the financial results also highlight challenges for Aarti Drugs. The company's cash and cash equivalents have reached their lowest point in the last six half-yearly periods, recorded at Rs 7.56 crore. This decline indicates a tightening of short-term liquidity, which could impact operational flexibility.
Overall, Aarti Drugs' recent financial performance showcases a mix of positive growth in profitability alongside concerns regarding liquidity.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
